Ovid Therapeutics (OVID) Short Interest Ratio & Short Volume → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free OVID Stock Alerts $3.06 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Ovid Therapeutics Short Interest DataCurrent Short Interest2,850,000 sharesPrevious Short Interest2,820,000 sharesChange Vs. Previous Month+1.06%Dollar Volume Sold Short$9.46 millionShort Interest Ratio14.6 Days to CoverLast Record DateMay 15, 2024Outstanding Shares70,940,000 sharesFloat Size57,530,000 sharesShort Percent of Float4.95%Today's Trading Volume78,572 sharesAverage Trading Volume96,813 sharesToday's Volume Vs. Average81% Short Selling Ovid Therapeutics ? Sign up to receive the latest short interest report for Ovid Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOVID Short Interest Over TimeOVID Days to Cover Over TimeOVID Percentage of Float Shorted Over Time Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Ovid Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20242,850,000 shares $9.46 million +1.1%5.0%14.6 $3.32 4/30/20242,820,000 shares $8.60 million +0.7%4.8%13.7 $3.05 4/15/20242,800,000 shares $8.96 million No Change4.8%13.4 $3.20 3/31/20242,800,000 shares $8.54 million -23.7%4.8%13.7 $3.05 3/15/20243,670,000 shares $9.98 million +0.6%6.3%17.4 $2.72 2/29/20243,650,000 shares $12.41 million +1.4%6.2%22.9 $3.40 Get the Latest News and Ratings for OVID and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/20243,600,000 shares $13.10 million +7.8%6.1%23.9 $3.64 1/31/20243,340,000 shares $12.93 million +8.4%5.6%23.5 $3.87 1/15/20243,080,000 shares $9.64 million +6.2%5.2%21.9 $3.13 12/31/20232,900,000 shares $9.34 million +16.9%4.9%21.3 $3.22 12/15/20232,480,000 shares $8.53 million +7.8%4.2%18.2 $3.44 11/30/20232,300,000 shares $6.84 million +7.5%3.9%19.2 $2.98 11/15/20232,140,000 shares $7.19 million +6.5%3.7%18 $3.36 10/31/20232,010,000 shares $7.14 million +2.6%3.5%13.2 $3.55 10/15/20231,960,000 shares $7.19 million -5.3%3.4%12.3 $3.67 9/30/20232,070,000 shares $7.95 million +2.0%3.6%13.4 $3.84 9/15/20232,030,000 shares $8.06 million -2.4%3.5%11.9 $3.97 8/31/20232,080,000 shares $7.00 million +12.4%3.6%6.6 $3.37 8/15/20231,850,000 shares $6.64 million +1.1%3.2%5.9 $3.59 7/31/20231,830,000 shares $6.57 million -0.5%3.1%6.3 $3.59 7/15/20231,840,000 shares $6.24 million No Change3.3%6.4 $3.39 6/30/20231,840,000 shares $6.04 million +216.7%3.3%6.4 $3.28 6/15/2023581,000 shares $2.08 million +40.2%1.0%2.2 $3.58 5/31/2023414,500 shares $1.47 million +28.7%0.7%3.3 $3.54 5/15/2023322,100 shares $1.12 million +62.3%0.6%3.2 $3.49 4/30/2023198,500 shares $710,630.00 -7.2%0.4%2.2 $3.58 4/15/2023213,900 shares $663,090.00 +2.6%0.4%2.9 $3.10 3/31/2023208,500 shares $537,930.00 -9.8%0.4%3 $2.58 3/15/2023231,200 shares $483,208.00 -5.5%0.4%3.3 $2.09 2/28/2023244,600 shares $604,162.00 +9.1%0.4%2.7 $2.47 2/15/2023224,300 shares $567,479.00 -1.1%0.4%2.6 $2.53 1/31/2023226,700 shares $566,750.00 +3.1%0.4%2.6 $2.50 1/15/2023219,800 shares $523,124.00 +2.9%0.4%2.5 $2.38 12/30/2022213,600 shares $397,296.00 -24.7%0.4%1.8 $1.86 12/15/2022283,500 shares $510,300.00 +4.5%0.5%2.4 $1.80 11/30/2022271,200 shares $480,024.00 -5.8%0.5%2.6 $1.77 11/15/2022287,800 shares $483,504.00 +3.6%0.5%2.8 $1.68 10/31/2022277,700 shares $452,651.00 -3.7%0.5%2.6 $1.63 10/15/2022288,300 shares $449,748.00 +1.8%0.5%2.6 $1.56 9/30/2022283,100 shares $520,904.00 +1.9%0.5%3.1 $1.84This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. 9/15/2022277,800 shares $608,382.00 -3.5%0.5%2.7 $2.19 8/31/2022287,800 shares $578,478.00 +2.5%0.5%2.1 $2.01 8/15/2022280,800 shares $634,608.00 -6.8%0.5%1.6 $2.26 7/31/2022301,200 shares $617,460.00 -11.7%0.5%1.7 $2.05 7/15/2022341,100 shares $689,022.00 -6.9%0.7%1.9 $2.02 6/30/2022366,400 shares $787,760.00 -9.4%0.7%2 $2.15 6/15/2022404,500 shares $728,100.00 -31.7%0.8%2.1 $1.80 5/31/2022592,200 shares $1.00 million -5.5%1.1%3.3 $1.69 5/15/2022626,400 shares $1.37 million -6.9%1.2%3.9 $2.19 4/30/2022672,700 shares $1.85 million -5.6%1.3%4.4 $2.75 4/15/2022712,800 shares $2.29 million -3.0%1.4%3.9 $3.21 3/31/2022735,000 shares $2.31 million +0.3%1.4%3.7 $3.14 3/15/2022733,000 shares $2.29 million +5.3%1.4%3.7 $3.13 2/28/2022696,000 shares $2.36 million +7.2%1.4%3.2 $3.39 2/15/2022649,000 shares $2.08 million -9.2%1.3%3 $3.21 1/31/2022715,000 shares $1.97 million -0.5%1.4%3.1 $2.76 1/15/2022718,800 shares $2.25 million -3.9%1.5%3.3 $3.13 12/31/2021748,200 shares $2.40 million +4.1%1.5%3.6 $3.21 12/15/2021718,600 shares $2.31 million -4.1%1.5%3.1 $3.21 11/30/2021749,200 shares $2.51 million +13.0%1.5%3.4 $3.35 11/15/2021663,000 shares $2.41 million -39.2%1.3%2.7 $3.64 10/29/20211,090,000 shares $3.71 million -4.4%2.2%4.1 $3.40 10/15/20211,140,000 shares $4.10 million +10.7%2.3%4.1 $3.60 9/30/20211,030,000 shares $3.46 million -13.5%2.1%3.4 $3.36 9/15/20211,190,000 shares $4.12 million -26.5%2.5%2.7 $3.46 8/31/20211,620,000 shares $5.72 million -4.1%3.5%3.1 $3.53 8/13/20211,690,000 shares $6.83 million +3.7%3.6%2.8 $4.04 7/30/20211,630,000 shares $6.08 million -1.2%3.5%2.4 $3.73 7/15/20211,650,000 shares $6.09 million -1.2%3.5%2.2 $3.69 6/30/20211,670,000 shares $6.53 million -52.6%3.6%2 $3.91 6/15/20213,520,000 shares $15.52 million +0.6%6.5%4.4 $4.41 5/28/20213,500,000 shares $14.53 million -6.2%6.5%3.7 $4.15 5/14/20213,730,000 shares $12.31 million -11.8%N/A1.2 $3.30 4/30/20214,230,000 shares $16.37 million -10.2%N/A1.2 $3.87 4/15/20214,710,000 shares $18.13 million -18.5%N/A1.2 $3.85 3/31/20215,780,000 shares $22.25 million -29.1%N/A1.4 $3.85 3/15/20218,150,000 shares $33.42 million +153.1%N/A2 $4.10 2/26/20213,220,000 shares $9.50 million +17.1%8.4%0.7 $2.95 2/12/20212,750,000 shares $9.19 million -6.5%7.2%1.2 $3.34 1/29/20212,940,000 shares $7.67 million -8.4%8.2%1.4 $2.61 1/15/20213,210,000 shares $8.25 million -7.2%8.9%1.8 $2.57 12/31/20203,460,000 shares $8.23 million -10.1%9.6%2.3 $2.38 12/15/20203,850,000 shares $10.16 million +11.3%10.7%2.8 $2.64 11/30/20203,460,000 shares $21.76 million +13.4%9.6%3.1 $6.29 11/15/20203,050,000 shares $18.42 million +15.1%8.5%3.2 $6.04 10/30/20202,650,000 shares $13.91 million +0.8%6.9%2.8 $5.25 10/15/20202,630,000 shares $14.96 million -38.0%6.9%2.7 $5.69 9/30/20204,240,000 shares $24.34 million +20.8%11.1%4.2 $5.74 9/15/20203,510,000 shares $22.50 million -22.5%9.9%2.9 $6.41 8/31/20204,530,000 shares $26.00 million +51.0%12.7%2.8 $5.74This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. 8/14/20203,000,000 shares $22.50 million +2.7%9.7%1.8 $7.50 7/31/20202,920,000 shares $18.83 million +15.4%9.5%2 $6.45 7/15/20202,530,000 shares $18.60 million -30.1%8.6%1.7 $7.35 6/30/20203,620,000 shares $26.68 million +170.2%12.3%2.5 $7.37 6/15/20201,340,000 shares $7.60 million +58.6%4.6%1.1 $5.67 5/29/2020844,800 shares $4.52 million -37.4%2.9%1 $5.35 5/15/20201,350,000 shares $5.55 million -18.2%4.6%1.7 $4.11 4/30/20201,650,000 shares $6.01 million +20.4%5.7%2.7 $3.64 4/15/20201,370,000 shares $4.64 million +8.7%4.7%2.5 $3.39 3/31/20201,260,000 shares $4.30 million -43.2%4.4%2.2 $3.41 3/13/20202,216,300 shares $6.29 million +21.8%9.8%3.5 $2.84 2/28/20201,820,000 shares $4.40 million +94.6%8.0%2.7 $2.42 2/14/2020935,500 shares $2.88 million -14.2%4.2%1.3 $3.08 1/31/20201,090,000 shares $3.52 million +27.0%5.1%1.5 $3.23 1/15/2020858,500 shares $3.41 million +5.8%4.0%1.2 $3.97 12/31/2019811,800 shares $2.88 million +234.6%3.6%1.2 $3.55 8/15/2019384,800 shares $750,360.00 -21.3%1.7%1.2 $1.95 OVID Short Interest - Frequently Asked Questions What is Ovid Therapeutics' current short interest? Short interest is the volume of Ovid Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 2,850,000 shares of OVID short. 4.95% of Ovid Therapeutics' shares are currently sold short. Learn More on Ovid Therapeutics' current short interest. What is a good short interest ratio for Ovid Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OVID shares currently have a short interest ratio of 15.0. Learn More on Ovid Therapeutics's short interest ratio. What is a good short interest percentage for Ovid Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.95% of Ovid Therapeutics' floating shares are currently sold short. Is Ovid Therapeutics' short interest increasing or decreasing? Ovid Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,850,000 shares, an increase of 1.1% from the previous total of 2,820,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Ovid Therapeutics' float size? Ovid Therapeutics currently has issued a total of 70,940,000 shares. Some of Ovid Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ovid Therapeutics currently has a public float of 57,530,000 shares. How does Ovid Therapeutics' short interest compare to its competitors? 4.95% of Ovid Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Ovid Therapeutics: Immunic, Inc. (3.13%), Tyra Biosciences, Inc. (7.69%), Disc Medicine, Inc. (15.22%), Zentalis Pharmaceuticals, Inc. (26.09%), CureVac (3.94%), 89bio, Inc. (10.29%), Centessa Pharmaceuticals plc (2.90%), PureTech Health plc (0.02%), Cogent Biosciences, Inc. (14.08%), Evolus, Inc. (8.63%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Ovid Therapeutics stock? Short selling OVID is an investing strategy that aims to generate trading profit from Ovid Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ovid Therapeutics? A short squeeze for Ovid Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OVID, which in turn drives the price of the stock up even further. How often is Ovid Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OVID, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: IMUX Short Squeeze TYRA Short Squeeze IRON Short Squeeze ZNTL Short Squeeze CVAC Short Squeeze ETNB Short Squeeze CNTA Short Squeeze PRTC Short Squeeze COGT Short Squeeze EOLS Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OVID) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
